JANX · Insider Trading
Janux Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by JANX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | David Alan Campbell | President and CEO | G | −123,840 | — |
| 2026-07-10 | David Alan Campbell | President and CEO | M | +7,000 | +$29.47K |
| 2026-06-12 | Eric Dobmeier | Director | A | +5,500 | — |
| 2026-06-12 | Jake Simson | Director | A | +5,500 | — |
| 2026-06-12 | Winston Kung | Director | A | +5,500 | — |
| 2026-06-12 | Natasha Hernday | Director | A | +5,500 | — |
| 2026-06-12 | Ronald W Barrett | Director | A | +5,500 | — |
| 2026-06-12 | Vickie L Capps | Director | A | +5,500 | — |
| 2026-06-12 | RA Capital Healthcare Fund LP | Director | A | +27,500 | — |
| 2026-06-04 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | Sell | −4,059 | −$56.94K |
| 2026-05-13 | Maria Dobek | Vice President, Accounting | Sell | −2,038 | −$28.88K |
| 2026-02-04 | William Go | Chief Medical Officer | A | +44,000 | — |
| 2026-01-02 | Charles M. Winter | Chief Technical Officer | MIXED | +26,199 | −$32.97K |
| 2026-01-02 | Zachariah McIver | Chief Medical Officer | MIXED | +26,286 | −$37.26K |
| 2026-01-02 | Maria Dobek | Vice President, Accounting | MIXED | +17,473 | −$20.07K |
| 2026-01-02 | Thomas DiRaimondo | Chief Scientific Officer | MIXED | +28,895 | −$34.39K |
| 2026-01-02 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | A | +36,000 | — |
| 2026-01-02 | David Alan Campbell | President and CEO | MIXED | +88,528 | −$110.83K |
| 2026-01-02 | Andrew Hollman Meyer | Chief Business Officer | Sell | −1,879 | −$25.80K |
| 2025-12-03 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$74.63K |
| 2025-11-14 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$64.69K |
| 2025-10-30 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$388.30K |
| 2025-06-13 | Alana B. McNulty | Director | A | +3,750 | — |
| 2025-06-13 | Vickie L Capps | Director | A | +3,750 | — |
| 2025-06-13 | Eric Dobmeier | Director | A | +3,750 | — |
| 2025-06-13 | Natasha Hernday | Director | A | +3,750 | — |
| 2025-06-13 | Ronald W Barrett | Director | A | +3,750 | — |
| 2025-06-13 | Jake Simson | Director | A | +3,750 | — |
| 2025-06-13 | Winston Kung | Director | A | +3,750 | — |
| 2025-06-13 | Sheila Gujrathi | Director | A | +3,750 | — |
| 2025-06-13 | RA Capital Nexus Fund II, L.P. | Director | A | +18,750 | — |
| 2025-06-04 | Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | A | +44,000 | — |
| 2025-05-02 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$92.71K |
| 2025-04-23 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$85.98K |
| 2025-03-07 | Rajeev M. Shah | Director | Buy | +4,120,205 | +$126.71M |
| 2025-03-05 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$93.14K |
| 2025-02-05 | Andrew Hollman Meyer | Chief Business Officer | MIXED | — | −$126.96K |
| 2025-01-08 | David Alan Campbell | President and CEO | Sell | −5,000 | −$300.00K |
| 2025-01-03 | Thomas DiRaimondo | Chief Scientific Officer | A | +24,000 | — |
| 2025-01-03 | David Alan Campbell | President and CEO | A | +81,000 | — |
| 2025-01-03 | Maria Dobek | Vice President, Accounting | A | +14,000 | — |
| 2025-01-03 | Byron Robinson | Chief Strategy Officer | A | +28,000 | — |
| 2025-01-03 | Andrew Hollman Meyer | Chief Business Officer | MIXED | +4,666 | −$731.79K |
| 2025-01-03 | Zachariah McIver | Chief Medical Officer | A | +26,000 | — |
| 2025-01-03 | Charles M. Winter | Chief Technical Officer | A | +23,000 | — |
| 2024-12-27 | David Alan Campbell | President and CEO | Sell | −25,000 | −$1.40M |
| 2024-12-20 | Andrew Hollman Meyer | Chief Business Officer | M | +9,881 | +$199.99K |
| 2024-12-03 | David Alan Campbell | President and CEO | Sell | −15,000 | −$1.00M |
| 2024-11-27 | David Alan Campbell | President and CEO | Sell | −25,000 | −$1.29M |
| 2024-11-07 | Sheila Gujrathi | Director | J | +4,611 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | Director | 10,031,081 | $167.42M |
| RA Capital Nexus Fund II, L.P. | Director | 1,048,406 | $17.50M |
| David Alan Campbell | President and CEO | 264,742 | $4.42M |
| Thomas DiRaimondo | Chief Scientific Officer | 155,825 | $2.60M |
| Sheila Gujrathi | Director | 118,889 | $1.98M |
| Charles M. Winter | Chief Technical Officer | 106,321 | $1.77M |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 | $1.39M |
| Vickie L Capps | Director | 79,598 | $1.33M |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 | $1.27M |
| William Go | Chief Medical Officer | 44,000 | $734.36K |
| Maria Dobek | Vice President, Accounting | 32,270 | $538.59K |
| Byron Robinson | Chief Strategy Officer | 28,000 | $467.32K |
| Zachariah McIver | Chief Medical Officer | 23,286 | $388.64K |
| Natasha Hernday | Director | 15,481 | $258.38K |
| Eric Dobmeier | Director | 15,481 | $258.38K |
| Jake Simson | Director | 11,750 | $196.11K |
| Winston Kung | Director | 11,750 | $196.11K |
| Ronald W Barrett | Director | 11,750 | $196.11K |
| RA Capital Healthcare Fund LP | Director | 11,750 | $196.11K |
| Alana B. McNulty | Director | 6,250 | $104.31K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JANX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.